|
|
|
20 Feb 2008 |
Antisense Therapeutics Ltd Licenses ATL1102 to Teva Pharmaceutical Industries Ltd.
|
|
20 Feb 2008 |
Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
|
|
18 Feb 2008 |
Takeda Discontinues Development of Matuzumab
|
|
18 Feb 2008 |
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
|
|
12 Feb 2008 |
Sanofi-aventis enters into Antibody Agreements with Dyaxand "Phage Display Technology"
|
|
12 Feb 2008 |
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
|
|
08 Feb 2008 |
TopoTarget Clarifies Status of Collaboration with LEO-Pharma, in order to Fully Ensure Accurate and FullI nformation to the market
|
|
06 Feb 2008 |
Meditrina Pharmaceuticals, Inc. Announces exclusive global license agreement with AstraZeneca
|
|
05 Feb 2008 |
4SC and AiCuris begin collaboration for the discovery of anti-infective drug candidates
|
|
05 Feb 2008 |
Manhattan Pharmaceuticals Announces Joint Venture With Nordic Biotech for Lead Product Hedrin
|
|
04 Feb 2008 |
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
|
|
04 Feb 2008 |
GlaxoSmithKline and Amira Pharmaceuticals enter global agreement for FLAP inhibitor programme
|
|
01 Feb 2008 |
Glenmark Pharmaceuticals to get back the Global Rights to Melogliptin, GRC 8200 from Merck Serono
|
|
30 Jan 2008 |
Iroko Pharmaceuticals Acquires Rights to Cardiovascular Product from Merck & Co., Inc. (MRK)
|
|
29 Jan 2008 |
Abbott and Eisai Finalize License Agreement in Japan for Additional Indications for Adalimumab, The Only Fully Human Monoclonal anti-TNFalpha Antibody
|
|
28 Jan 2008 |
Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor
|
|
28 Jan 2008 |
Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
|
|
28 Jan 2008 |
Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
|
|
25 Jan 2008 |
TransTech Pharma, Inc. Acquires Three Programs for the Treatment of Metabolic Disorders from Novo Nordisk
|
|
24 Jan 2008 |
Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
|
|
22 Jan 2008 |
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
|
|
22 Jan 2008 |
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
|
|
18 Jan 2008 |
GSK Does Not Option XL784 for Further Development
|
|
16 Jan 2008 |
Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor
|
|
15 Jan 2008 |
Alfacell Corporation Licenses ONCONASE(R) U.S. Commercial Rights to Strativa Pharmaceuticals
|
|
14 Jan 2008 |
Inspire Announces Its Termination of Bilastine Licensing Agreement
|
|
14 Jan 2008 |
Three Rivers PharmaceuticalsŪ, LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
|
|
08 Jan 2008 |
Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
|
|
08 Jan 2008 |
Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech
|
|
07 Jan 2008 |
Osiris Therapeutics Regains Worldwide Rights to Cardiovascular Indications for Prochymal(TM)
|
|
07 Jan 2008 |
Tacere Therapeutics Eenters Collaborationa and License Agreement With Pfizer to Develop and Commercilize RNAi Hepatitis C Drug
|
|
07 Jan 2008 |
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
|
|
03 Jan 2008 |
Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies
|
|
03 Jan 2008 |
Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia
|
|
02 Jan 2008 |
Nalmefene United Kingdom and Ireland rights acquired by Lundbeck
|
|
02 Jan 2008 |
Sepracor Inc. and Bial Announce Exclusive Licensing Agreement for Development and Commercialization of Anti-Epileptic Compound in United States and Canada
|
|
31 Dec 2007 |
IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
|
|
27 Dec 2007 |
Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
|
|
21 Dec 2007 |
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
|
|
21 Dec 2007 |
Medivir AB and Presidio Pharmaceuticals, Inc. Amend license agreement
|
|
20 Dec 2007 |
Human Genome Sciences and Aegera Therapeutics announce licensing and collaboration agreement on novel anti-cancer drugs
|
|
20 Dec 2007 |
License Agreement for New Therapeutic Agent for Thrombocytopenia
|
|
19 Dec 2007 |
Merck KGaA and Idera Pharmaceuticals to Collaborate on Development of TLR9 Agonists for Treatment of Cancer
|
|
19 Dec 2007 |
Cystic Fibrosis: License Agreement Boosts Development of Therapy
|
|
17 Dec 2007 |
Novo Nordisk licenses global rights to potential new haemostasis therapy
|
|
17 Dec 2007 |
Lilly and BioMS Medical Announce Global Licensing and Development Agreement
|
|
14 Dec 2007 |
Shire expands its gastrointestinal portfolio through in-licensing Celiac disease Phase 2 product from Alba Therapeutics Corporation
|
|
05 Dec 2007 |
BioAlliance Pharma acquires the European commercialization rights to pafuramidine for the treatment of Pneumocystis carinii pneumonia
|
|
05 Dec 2007 |
GTC Biotherapeutics Obtains Licenses to Factor IX, Factor VIII and Fibrinogen
|
|
05 Dec 2007 |
Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds
|
| |
|
Results 151 - 200 of 814 |
